Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

被引：0
|
作者：
Weiwei Huang
Chenxi Wang
Yangkun Shen
Qi Chen
Zhijian Huang
Jian Liu
Xiaoyan Lin
Lili Wang
Fan Wu
Xinhua Chen
Nani Li
Yi Hong
Mulan Chen
Jieyu Li
Chuanzhong Huang
机构：
[1] Fujian Medical University Union Hospital,Department of Medical Oncology
[2] Clinical Oncology School of Fujian Medical University,Department of Medical Oncology
[3] Fujian Cancer Hospital,Fujian Key Laboratory of Translational Cancer Medicine
[4] Fujian Cancer Hospotial,Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China
[5] Fujian Normal University Qishan Campus,Department of Breast Surgical Oncology
[6] Clinical Oncology School of Fujian Medical University,Laboratory of Immuno
[7] Fujian Cancer Hospital,Oncology
[8] Clinical Oncology School of Fujian Medical University,undefined
[9] Fujian Cancer Hospital,undefined
来源：
BMC Cancer | / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer
    Haiderali, Amin
    Rhodes, Whitney C.
    Gautam, Santosh
    Huang, Min
    Sieluk, Jan
    Skinner, Karen E.
    Schwartzberg, Lee S.
    FUTURE ONCOLOGY, 2021, 17 (29) : 3819 - 3831
  • [22] A real-world retrospective study of apatinib plus chemotherapy in metastatic breast cancer.
    Zhu, Anjie
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Li, Qing
    Zhang, Pin
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [24] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [25] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [26] Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices
    Tan, Ruoding
    Cassoli, Lourenia
    Yan, Ying
    Shen, Vincent
    Day, Bann-mo
    Mitchell, Edith P.
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [27] Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real-world findings
    Kish, J. K.
    Mougalian, S. S.
    Copher, R.
    McAllister, L.
    Zhixiao, W.
    Broscious, M.
    CANCER RESEARCH, 2017, 77
  • [28] Real-world efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in Brazilian patients with earlystage triple-negative breast cancer
    Sousa, Isadora
    Comini, Ana Carolina M.
    Borges, Italo
    Balint, Flavia C.
    Martins, Livia Alexandre
    Sousa, Debora G.
    Sanches, Solange M.
    Cesca, Marcelle G.
    Cordeiro de Lima, Vladmir
    Tavares, Monique
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer A Multi-institutional Real-world Report on Efficacy and Safety
    Valerio, Maria R.
    Arrivas Bajardi, Eugenia
    Arcara, Carmelo C.
    Borsellino, Nicolo'
    Lo Mauro, Mario
    Cipolla, Calogero
    Santarpia, Mariacarmela
    Firenze, Alberto
    Motta, Gianmarco
    Vigneri, Paolo
    Gebbia, Vittorio
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (03): : 105 - 108
  • [30] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Zhang, Qingyuan
    Shao, Bin
    Tong, Zhongsheng
    Ouyang, Quchang
    Wang, Yuting
    Xu, Guoying
    Li, Shaorong
    Li, Huiping
    BMC MEDICINE, 2022, 20 (01)
12345